Physician profile
Pawan Sahu
NPI 1750327516
$2,243.30
in general payments reported to CMS, 2019-2025
23 companies · $448 in 2025
The $448 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $467 · 2020: $98.85 · 2021: $85.34 · 2022: $175 · 2023: $397 · 2024: $573 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275 · Gift: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.06 |
| Gift | $142.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $510.55 | 2019-2025 | Skyrizi, Rinvoq, Viberzi |
| Braintree Laboratories, INC. | $396.44 | 2021-2025 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $272.11 | 2019-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $129.14 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $116.79 | 2019-2025 | Eohilia, Entyvio |
| Janssen Biotech, INC. | $94.86 | 2019-2025 | Tremfya |
| Boston Scientific Corporation | $89.38 | 2019-2024 | Resolution Clip, Cre Pro |
| Gilead Sciences, INC. | $84.48 | 2019-2024 | |
| Pfizer INC. | $68.93 | 2019-2025 | |
| Qol Medical, LLC | $66.41 | 2025 | Sucraid |
| Celgene Corporation | $58.16 | 2023-2024 | Zeposia |
| Genzyme Corporation | $49.21 | 2023-2024 | |
| Daiichi Sankyo INC. | $44.47 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $44.17 | 2023-2025 | Dupixent |
| Shionogi INC | $36.81 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $35.52 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $35.19 | 2019-2023 | Rebyota |
| Celltrion USA INC. | $25.70 | 2024 | Vegzelma |
| Ironwood Pharmaceuticals, INC | $24.31 | 2023 | Linzess |
| Dova Pharmaceuticals | $19.72 | 2019 | |
| Aimmune Therapeutics, INC. | $15.61 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $13.39 | 2022 | |
| Echosens North America, INC. | $11.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pawan Sahu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.